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Background: More accurate phenotyping of COPD is of great interest since it may have 
  prognostic and therapeutic consequences. We attempted to explore the possible relationship 
between the extent of emphysema, as assessed by high-resolution computed tomography 
(HRCT), and COPD severity. We also included some study variables involving exercise   tolerance 
  evaluation and peripheral muscle strength (PMS) measurement.
Methods: Sixty-four patients with COPD (mean age 64 ± 7 years) were enrolled in a prospective 
observational cross-sectional study. All patients underwent clinical and functional evaluations: 
assessment of dyspnea, body mass index (BMI), health status assessment, spirometry testing, 
and arterial blood gas analysis. The extent of emphysema was graded using HRCT. Functional 
capacity was evaluated by a cardiopulmonary maximal exercise testing (CPET), the shuttle 
walking test, and by estimation of PMS.
Results: Half of the study patients had an emphysematous phenotype. There was a significant 
correlation between the score derived from analysis of HRCT images and BMI and   respiratory 
functional parameters, as well as VO2 max (maximal oxygen uptake) and chest pull 1RM 
(1 rep max). Compared with subjects with a nonemphysematous phenotype, those with an 
  emphysematous phenotype showed a lower BMI, a reduced PMS, and displayed a lower power 
at CPET. Significant differences in lung function tests were found for diffusing capacity and 
hyperinflation. No significant differences in quality of life were observed between the two 
study groups.
Conclusions: Compared with subjects with a nonemphysematous phenotype, subjects with 
an emphysematous phenotype has a different profile in terms of BMI, lung function, PMS, and 
exercise capacity.
Keywords: chronic obstructive pulmonary disease, exercise tolerance, emphysema, phenotypes, 
lung function
Introduction
Chronic obstructive pulmonary disease (COPD) is a disease state characterized by 
airflow limitation that is not fully reversible and usually progressive.1 This airflow 
limitation may be caused by both inflammation and wall thickening in small airways, 
which is responsible for the narrowing of the airway lumens, and in some but not 
all cases, parenchymal destruction of the lungs (emphysema), leading to loss of the 
elastic lung recoil.2 Traditionally, on the basis of determined clinical, functional, and 
radiologic features, patients with COPD used to be classified into 2 different biotypes: 
the “blue boater”, in association with a predominant chronic bronchitis condition, and 
the “pink puffer”, identified as predominant emphysema.3 However these are only the International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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two extreme phenotypes among the broad variety of clinical 
presentations in COPD.
Studies conducted in recent years have revealed that 
patients with the same stage of disease may offer   different 
pathological changes,4–6 and classic COPD phenotypes 
clearly differ from these based on severity of emphysema as 
assessed by high resolution computed tomography (HRCT) 
scanning.4
Based on studies with HRCT support, some authors 
find that patients with the phenotype in which emphysema 
predominates have more severe lung function impairment 
but more intense airway inflammation and a higher BODE 
index (body mass index, airflow obstruction, dyspnea, 
  exercise capacity) and subsequently, a possible more serious 
systemic dysfunction.7 In contrast, other studies show that 
the severity of emphysema is highly variable even among 
subjects with the same functional stage of COPD, which 
does not support emphysema as the major cause of airflow 
limitation in COPD.4
In COPD patients, health-status measurement and the 
BODE score predicts mortality better than FEV1 (forced 
expiratory volume in the first second of expiration) since 
FEV1 is a component of BODE.8,9 These multidimensional 
tools may be more valuable because they can reflect the 
systemic nature of the disease. Other parameters, such as 
physical activity and exercise tolerance as measured by cycle 
ergometry, have been demonstrated to be strong independent 
predictors of COPD mortality.10,11 In addition, peripheral 
muscle strength12 and muscle mass depletion,13 which do 
reflect the skeletal muscle dysfunction present in COPD 
patients, also offer prognostic information. Some authors 
state that these comorbid manifestations are more frequent 
in patients with predominant emphysema, what would imply 
a poorer prognosis.14
Consequently more accurate phenotyping of COPD is of 
great interest since it may have prognostic and therapeutic 
consequences. We attempt to explore the possible relation-
ship between emphysema extension as assessed by HRCT, 
and COPD severity. Our hypothesis is that patients with 
predominant emphysema have a greater systemic dysfunc-
tion, and then show evidence of lower exercise capacity and 
peripheral muscle strength than those with COPD not associ-
ated with emphysema. To clarify the differences between the 
morphological phenotypes and clinical features of COPD, 
we classified patients into 2 phenotypes according to the 
dominance of emphysema on chest HRCT and examined 
the clinical characteristics, including exercise and muscle 
function, in each phenotype.
Material and methods
study participants
Sixty-four male patients with age-related COPD were 
enrolled in a prospective, observational, cross-sectional 
study. The study was approved by the Institutional Review 
Board and written informed consent was obtained from all 
participants. Patients were recruited from the outpatient 
clinic. Inclusion criteria were: 1) being an adult patient with 
a diagnosis of COPD according to international guidelines,9 
and 2) being clinically stable during the previous 3 months. 
The exclusion criteria were: 1) unwillingness to participate 
in the study, 2) a history of recent exacerbation (,3 months) 
requiring systemic corticosteroids or antibiotics, and 3) any 
contraindication or inability to perform the study tests.15
All patients underwent clinical and functional   evaluations 
that included assessment of dyspnea, body mass index (BMI),16 
health status assessment, spirometry testing, and   arterial 
blood gas analysis. These were followed by   assessments of 
physical function and radiological   examinations consisting 
of HRCT scans. The functional capacity of the study partici-
pants was evaluated by cardiopulmonary maximal exercise 
testing (CPET), the shuttle walking test (SWT),17 and by 
estimation of peripheral muscle strength (PMS).
Dyspnea scale
Basal dyspnea was measured using the modified Medical 
Research Council scale (mMRC)18 which classifies the degree 
of dyspnea ranging from 0 to 4.
Pulmonary function tests
Spirography was performed using a   pneumotachograph 
  spirograph (Masterlab, Erich Jaeger GMBH,   Wuerzburg, 
Germany) following the SEPAR19 and the ATS20 
  recommendations. Static lung volumes were determined 
plethysmographically.21 Arterial blood gas analysis was 
  carried out according to the SEPAR22 recommendations.
health-related quality of life
For the assessment of quality of life, we used a specific ques-
tionnaire for patients with COPD, the Chronic Respiratory 
Disease Questionnaire (CRDQ) proposed by Guyatt, which 
has been previously validated and translated into Spanish.23 
It consists of 20 items rated from 1 to 7 (so that the higher 
the score better quality of life) and divided into 4 sections: 
dyspnea (questions 4a–4e), fatigue (questions 7, 10, 14, 16), 
emotional functioning (questions 5, 8, 11, 13, 15, 17, 19), 
and mastery (questions 6, 9, 12, 18). Normal range should 
be the maximum amount for all items, which means 7 points International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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in each section and 28 in total (the maximum amount of the 
4   sections). The changes are considered clinically signifi-
cant when the score for each question increased by at least 
0.5 points on the overall score for each of the paragraphs 
(0.5–1: slight change; 1–1.5: moderate; $1.5: excellent).
Peripheral muscle strength
Weight-lifting capacity was measured as the heaviest weight 
that could be lifted once throughout the complete range of 
movement (1RM test, 1 rep max test).24 Typical PMS values 
were described by Hamilton et al.25
shuttle walking test
The SWT was conducted as described by Singh et al,26 
which requires patients to walk a 10 m course marked out 
by 2 cones with progressive levels. The maximum distance 
to walk is 1020 m.
Maximal cardiopulmonary exercise test
Maximal cardiopulmonary exercise testing was performed 
on a cycle ergometer (Collins Respiratory Ergomed, USA) 
according to international standards.15,27 Typical values were 
described by Wasserman et al.28 The following   variables 
were measured: oxygen consumption; carbon dioxide 
  production; an indirect assessment of anaerobic threshold, 
and the respiratory pattern (maximal breathing capacity, 
tidal volume, respiratory rate).29 The exercise was performed 
on   electrocardiographic, heart rate and   pulsioxymetric 
monitoring. All measurements were integrated into the cycle 
ergometer device (Collins Respiratory Ergomed, USA) and 
evaluated simultaneously during the test. After the exercise, 
we assessed heart rate, blood pressure, leg fatigue, chest pain, 
and dyspnea using the modified Borg’s scale.30
high-resolution computed tomography
HRCT was used to distinguish between emphysematous and 
non-emphysematous phenotypes. Acquisition   parameters 
were as follows: 1 mm collimation, 120 to 140 kV , 75 to 
350 mA, 0.75 to 1 seconds scanning time, and field of view 
350 to 400 mm. HRCT images were selected at 3 levels, 
including the aortic arch, the main carina, and 1 to 2 cm above 
the highest hemi-diaphragm. A window level of -700 to -900 
Hounsfield units (HU) with a 600 to 1600 HU window width 
were used for image interpretation.31 Two readers visually and 
independently assessed the severity of emphysema according 
to a modified scoring system adopted from previous studies 
with no knowledge of the patients’ clinical information.32 
We analyzed 6 images in 3 slices in the lungs; the total score 
from all images was considered as a representative value of 
the severity of emphysema in each person. Each image was 
classified as normal (score 0), up to 25% affected (score 1), 
up to 50% affected (score 2), up to 75% affected (score 3), 
and more than 75% affected (score 4), giving a minimum 
score of 0 and maximum of 24. Disagreement between the 
two radiologists was resolved by consensus. Emphysema was 
defined as the presence of a score .6, which means 25% of 
total area, according to Nakano et al.33
Data analysis
Quantitative variables were summarized with means and 
standard deviations. For descriptive purposes, variables are 
presented first for the entire study sample and thereafter 
according to the GOLD stages.1 Differences across differ-
ent GOLD stages were assessed on the basis of analysis of 
variance (ANOVA). Qualitative variables were compared 
between emphysematous and nonemphysematous patients 
using the chi-square test. The correlation between the 
study variables was estimated using Pearson’s correlation 
  coefficient (r). Quantitative variables were compared by 
Student’s t test. Data were analyzed by SPSS (SPSS Inc., 
Chicago IL, USA), version 14.0.
Results
Clinical and functional characteristics of the 64 patients are 
described in Table 1. Globally, our patients had a severe 
obstruction, hyperinflation, and hypoxemia. They had a 
mildly impaired pulmonary diffusion, and showed decreased 
exercise capacity and low HRQL and dyspnea indexes.
From the analysis of the HRCT images, we obtained 
scores ranging between 0 and 24 points. Based on 
these scores, half of the study participants (n = 32) 
were   classified as   emphysematous phenotype and half 
(n = 32) as   nonemphysematous phenotype; median score 
for the whole group was 8.5 ± 6.05 points. By groups, 
  emphysematous patients’ score was significantly higher 
than that of   nonemphysematous patients (12.4 ± 5.1 vs 
4.65 ± 4.075 points; P , 0.05). The mean attenuation values 
for the emphysema and nonemphysema groups were -889 
(32.3) HU and -865 (25) HU, respectively. The correlation 
study (Table 2) showed a significant relation between the 
HRTC score and BMI, dyspnea indexes, respiratory func-
tion parameters, VO2 max (maximal oxygen uptake), and 
chest pull 1RM.
When we separated patients into GOLD stages (Table 3), 
they were homogeneously distributed across the study 
groups. Patients with GOLD stages I and II were grouped International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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together since only 1 patient had stage I disease. Our results 
showed that the presence of emphysema is roughly equal 
across all levels of obstruction. PMS was similar in the three 
groups, but increasing GOLD stages were associated with a 
worsening of exercise capacity.
We differentiated COPD phenotypes according to 
HRCT findings (Table 4). Compared with nonemphy-
sematous patients, emphysematous patients had a lower 
BMI (26.5 [3.5] vs 31.4 [5.2]; P , 0.001), a reduced PMS 
(  Figure 1), and displayed a significantly lower power at 
CPET (54 [21.5] vs 67.9 [26.7] W; P , 0.05) (Figure 2). 
Both groups reached a similar distance in the SWT and 
there were no significant differences in HRQL indexes. It is 
important to note that because the grade of obstruction was 
not associated with a determined phenotype, both groups had 
a similar FEV1. Emphysematous patients showed a lower CO 
diffusion, lower FEV1/FVC ratio, and higher FVC, functional 
residual capacity (FRC), and total lung capacity (TLC) than 
nonemphysematous patients (Table 4).
Discussion
In this study, we have provided evidence that patients with 
an emphysematous phenotype have a different profile in 
terms of BMI, some measures of lung function, PMS, 
and exercise tolerance compared with nonemphysematous 
phenotype patients. Although lung function is required to 
diagnose COPD and classify its severity, FEV1 values are 
not generally associated with symptom intensity or exercise 
capacity.34 Moreover, the usefulness of FEV1 as a prognostic 
factor for clinical outcomes and mortality in COPD has been 
questioned. Accordingly, numerous other factors including 
dyspnea or acute exacerbations have been shown to sig-
nificantly affect survival.35,36 In recent years, there has been 
growing interest for patient-related outcomes in subjects 
with COPD, including clinical symptoms, the number of 
acute exacerbations, exercise tolerance, functional ability, 
and general well-being.37,38
Recent evidence has shown that different COPD 
  phenotypes may be significantly associated with   differences 
in BMI, health-related HRQL,4 small airway obstruction,39 
responsiveness to bronchodilators,5  and  systemic 
  inflammation.40 To our knowledge, however, there is a 
  paucity of information on the differences in physical function 
between emphysematous and nonemphysematous COPD 
patients.
Some authors have found no clinical or pulmonary func-
tional differences between emphysematous and nonemphy-
sematous patients.41 Other authors describe that patients with 
the phenotype in which emphysema predominates in HRCT 
are characterized by a severe pulmonary functional affect and 
a high airway inflammation.7 In our results, the severity of 
the emphysema varies even in patients with the same level 
of COPD. The grade of obstruction is not   associated with 
a determined phenotype as both groups showed a similar 
FEV1. Emphysematous patients had lower CO   diffusion, 
Table 1 Baseline characteristics of the 64 male study participants
Parameter Mean ± SD or %
Age, yr 64 ± 7
BMI, kg/m2 29 ± 5
CrDQ dyspnea 2.8 ± 0.7
CrDQ fatigue 4.2 ± 0.9
CrDQ emotional function 4.7 ± 0.9
CrDQ mastery 4.9 ± 1.2
CrDQ total 16.7 ± 2.9
FeV1 % predicted 42 ± 12
TLC % predicted 110 ± 15
rV % predicted 158 ± 37
KCO % predicted 84 ± 28
PaO2, mmhg 72 ± 11
PaCO2, mmhg 42 ± 5.5
CPeT power, W 61 ± 25
VO2 max, mL/min/kg 14.5 ± 3.7
PMs neck press, kg 24 ± 6.5
PMs chest pull, kg 42 ± 9.1
PMS butterfly, kg 19 ± 6.8
PMS flexion, kg 16.7 ± 6
PMs extension, kg 39 ± 11.7
sWT, m 380 ± 147
Abbreviations:  BMI,  body  mass  index;  CrDQ,  chronic  respiratory  disease 
questionnaire; FeV1, forced expiratory volume in the first second of expiration; 
TLC, total lung capacity; RV, residual volume; KCO, Krogh coefficient; PaO2, arterial 
oxygen partial pressure at rest; PaCO2, arterial carbon dioxide partial pressure at 
rest;  CPeT,  cardio-pulmonary  exercise  test;  VO2  max,  maximal  oxygen  uptake; 
PMs, peripheral muscle strength; sWT, shuttle walking test.
Table  2  Significant  relationships  between  HRCT  emphysema 
score and clinical variables in patients with COPD
Clinical variable r value P value
Dyspnea, mMrC 0.282 0.028
BMI, kg/m2 -0.4 0.001
PaCO2, mmhg -0.346 0.01
1rM chest pull, kg 0.3 0.032
VO2 max, mL/min/kg -0.274 0.03
FVC, % 0.346 0.01
FeV1/FVC, % -0.431 0.001
TLC, % 0.5 0.001
Abbreviations:  BMI,  body  mass  index;  PaCO2,  arterial  carbon  dioxide  partial 
pressure; FVC, forced vital capacity; FeV1, forced expiratory volume in the first second 
of expiration; TLC, total lung capacity; KCO, Krogh coefficient; mMRC, modified 
Medical research Council; 1rM, 1 rep max; VO2 max, maximal oxygen uptake.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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Table 3 Clinical and functional characteristics of the 64 male study participants
Characteristics GOLD I-II 
(n = 18)
GOLD III 
(n = 29)
GOLD IV 
(n = 17)
P value*
Age, yr 62 ± 6 65 ± 7 65 ± 7 ns
FeV1, % 57 ± 7.3 40 ± 5.6 25 ± 3.2 ,0.001
FeV1/FVC, % 48 ± 7.7 39 ± 6.5 28 ± 5 ,0.001
rV, % 141 ± 28.5 159 ± 34.9 189 ± 35 ,0.001
FrC, % 136 ± 18.8 148 ± 26 169 ± 30 ,0.001
TLC, % 109 ± 10.6 109 ± 17.4 112 ± 16 ns
Dyspnea, mMrC 2.3 ± 0.9 2.2 ± 0.7 2.7 ± 1 ns
BMI, kg/m2 29 ± 3.8 29 ± 5.5 27.8 ± 5.5 ns
PMs neck press, kg 25 ± 7 24 ± 7 22 ± 5 ns
PMs chest pull, kg 44 ± 11 41.7 ± 9 41 ± 6 ns
PMS butterfly, kg 19.5 ± 6.6 19.8 ± 7.6 17.5 ± 5.4 ns
PMS flexion, kg 17.4 ± 7.7 17 ± 4.7 15.6 ± 6.1 ns
sWT distance, m 39.5 ± 11.7 38.2 ± 12.6 40.4 ± 10.4 ns
sWT level 7.8 ± 2 7.1 ± 1 5.7 ± 1.7 0.001
CPeT power, watts  76.3 ± 27 61 ± 20.5 44.7 ± 20.4 ,0.001
VO2 max, mL/min/kg 17.2 ± 2.9 14 ± 3.3 12.5 ± 3.7 ,0.001
VO2 max, % 62 ± 11 54 ± 15.5 46.6 ± 13 0.007
emphysematous phenotype 9 (50%) 13 (44.8%) 10 (58.8%) ns
Notes: *Calculated by AnOVA or chi-square tests. Data are expressed as means and standard deviations or as absolute and relative frequencies for each group.
Abbreviations: CPET, cardio-pulmonary exercise test; NS, not significant; mMRC, modified Medical Research Council scale; BMI, body mass index; PMS, peripheral muscle 
strength; sWT, shuttle walking test; CPeT, cardio-pulmonary exercise test; VO2 max, maximal oxygen uptake; FeV1, forced expiratory volume in the first second of expiration; 
FVC, forced vital capacity; TLC, total lung capacity; rV, residual volume; FrC, functional residual capacity.
Table 4 Clinical and functional characteristics of the 64 male study participants according to COPD phenotype
Characteristics Non-emphysema 
(n = 32)
Emphysema  
(n = 32)
P value*
BMI, kg/cm2 31.4 ± 5.2 26.5 ± 3.5 ,0.001
FVC, % 78.3 ± 12.9 90.8 ± 16.1 0.002
FeV1, % 43.3 ± 10.9 41.2 ± 13.9 ns
FeV1/FVC, % 43.2 ± 9.6 36.9 ± 8.5 0.006
rV, % 152 ± 28 165 ± 45 ns
FrC, % 138 ± 21 158 ± 29 0.006
TLC, % 104 ± 12 117 ± 16 0.003
KCO, % 103 ± 25 65 ± 14 ,0.001
PaCO2, mmhg  44 ± 5.6 40 ± 4.9 0.013
PaO2, mmhg 70.6 ± 10.6 73.1 ± 11.9 ns
PMs neck press, kg 25 ± 7.5 23 ± 5 ns
PMs chest pull, kg  44.4 ± 10.2 39.9 ± 7.1 0.048
PMS butterfly, kg 21.3 ± 8.2 16.9 ± 3.9 0.010
PMS flexion, kg 18 ± 7 15.3 ± 4.3 0.089
PMs extension, kg 41.6 ± 12.9 36 ± 9.9 0.076
sWT distance, m 401 ± 142 359 ± 153 ns
CPeT power, watts 67.9 ± 26.7 54 ± 21.5 0.026
VO2 max, mL/min/kg 14.8 ± 3.9 14.3 ± 3.6 ns
VO2 max, % 57 ± 15.8 51.5 ± 13.2 ns
Notes: *Calculated by student’s t-test. Data are expressed as means and standard deviations.
Abbreviations: CPET, cardio-pulmonary exercise test; NS, not significant; mMRC, modified Medical Research Council scale; BMI, body mass index; CRDQ, chronic respiratory 
disease questionnaire; PMs, peripheral muscle strength; sWT, shuttle walking test; CPeT, cardio-pulmonary exercise test; VO2 max, maximal oxygen uptake; FeV1, forced 
expiratory volume in the first second of expiration; FVC, forced vital capacity; TLC, total lung capacity; RV, residual volume; FRC, functional residual capacity; PaCO2, arterial 
carbon dioxide partial pressure; PaO2, arterial oxygen partial pressure at rest.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 Differences in peripheral muscle strength between emphysema and nonemphysema patients.
Note: *statistically significant.
Abbreviation: PMs, peripheral muscle strength.
lower FEV1/FVC ratio, and higher FVC, FRC, and TLC than 
  nonemphysematous patients. Equally, BMI was   significantly 
lower in emphysematous patients. However these parameters 
did not vary by GOLD stages, which shows that they are 
related more to the grade of emphysema than to the grade 
of airway obstruction of the patients. In these subjects, 
the distance walked in the SWT was lower, which could 
be an expression of a greater affect on exercise capacity in 
emphysematous patients. This was confirmed in the maximum 
exercise capacity test, as emphysematous patients had lower 
CPET power.
Peripheral muscle weakness is commonly found in 
patients with COPD. Compared with normal subjects of 
0
CPET power (watt)
Non-emphysema
Emphysema
10
20
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60
70
Figure 2 Differences in cardio-pulmonary exercise test power between emphysema 
and nonemphysema patients.
Abbreviation: CPeT, cardio-pulmonary exercise test.
similar age, the reduction in quadriceps strength averages 
20% to 30% in patients with severe to moderate disease.42 
In this study, PMS was significantly more impaired in 
emphysematous than in nonemphysematous patients in the 
majority of 1RM maneuvers. In COPD, there is a loss of 
muscle mass and a muscle fiber-type shift from type I to type 
II accompanied by reduced activities of enzymes involved 
in oxidative energy metabolism.43 These changes have been 
associated with disease severity and BMI, but it is unclear 
whether fiber type redistribution is comparable between the 
COPD subtypes emphysema and chronic bronchitis.44 These 
modifications might affect impairment of muscle function, 
which we found to be associated with the emphysematous 
phenotype. Among COPD patients, upper limb strength 
is in general relatively well preserved compared with the 
lower limbs.45 The uneven distribution of muscle weakness 
between upper and lower limbs could be related to differ-
ences in accustomed level of activity between the different 
muscle groups. In this study, we found significant differences 
according to COPD phenotypes in both upper and lower 
body strength.
Peripheral muscle abnormalities and lung   hyperinflation 
may play a major role in the pathogenesis of exercise intoler-
ance among COPD patients.46 Lung hyperinflation has been 
related to a systemic inflammatory response, as resistive International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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breathing per se is an “immune challenge” for the body, 
elevating plasma cytokines and activating lymphocyte sub-
populations.47 It also has been shown that inspiratory fraction 
as an index of increased lung volumes is an independent 
predictor of maximal exercise capacity in patients with 
COPD.48 Moreover, inflammatory markers play an important 
part in muscle dysfunction and exercise intolerance.49 We 
have found a relationship between hyperinflation (total lung 
capacity and residual volume) and emphysematous patients, 
who have impaired exercise capacity. This could be due to 
the inflammation caused by hyperinflation, which is related 
to peripheral muscle dysfunction.
It  is  worth  noting  that  the  physical  capacity 
parameters – including exercise capacity and PMS – are 
patient-centered measurements which significantly affect 
patient health status.50 Makita et al4 found that subjects with 
severe emphysema had poorer quality of life scores, evalu-
ated using the St. George’s Respiratory Questionnaire, than 
those without emphysema. In our study, however, we were 
unable to find an association between HRQL and severity 
of emphysema. In turn, a significant negative relationship 
was found between emphysema score and the mMRC 
dyspnea scale.
A limitation of the study is that we used visual scoring to 
assess emphysema severity rather than objective quantifica-
tion. However, all HRCT images were thin-slice (,2 mm) 
and we carefully optimized the parameters for data analysis to 
obtain ideal images for assessment of emphysema. We were 
able to assess the overall percentage of emphysema and many 
investigators have demonstrated that a visual emphysema 
score for computer tomography images was highly correlated 
with objective volume-based computerized assessment.4,14 
Moreover, the sample size was not calculated by what 
we cannot say that the results have not reached   statistical 
  significance are not due to a small sample size.
In summary, we have shown that compared with subjects 
with a nonemphysematous phenotype, subjects with an 
emphysematous phenotype have a different profile in terms 
of BMI, lung function, PMS, and exercise tolerance. The 
severity of emphysema is highly variable, even in patients 
with the same GOLD stage. Our results point to major 
  differences among distinct phenotypes within COPD that 
should be taken into account in future studies.
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